Literature DB >> 9746255

Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection.

R P van Heeswijk1, R M Hoetelmans, P L Meenhorst, J W Mulder, J H Beijnen.   

Abstract

Nevirapine is a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1-infected patients. A simple and rapid high-performance liquid chromatographic method for the quantification of nevirapine in human plasma is described. Sample pretreatment consists of protein precipitation with acetonitrile. The analyte is separated from endogenous compounds by isocratic reversed-phase, ion-pair, high-performance liquid chromatography with ultraviolet detection at 282 nm. The method has been validated over the range of 52-10400 ng/ml using 250 microl of plasma. The assay was linear over this concentration range. Within- and between-day precisions were less than 4.5% for all quality control samples. The lower limit of quantitation was 52 ng/ml. Recovery of nevirapine from human plasma was 94.5%. This validated assay is suited for use in pharmacokinetic studies with nevirapine and can readily be used in a hospital laboratory for the monitoring of nevirapine concentrations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9746255     DOI: 10.1016/s0378-4347(98)00217-5

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  16 in total

1.  Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.

Authors:  Elin Svensson; Jan-Stefan van der Walt; Karen I Barnes; Karen Cohen; Tamara Kredo; Alwin Huitema; Jean B Nachega; Mats O Karlsson; Paolo Denti
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

Review 2.  Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

Authors:  Karen Dahri; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Supramolecular Complex of Ibuprofen with Larch Polysaccharide Arabinogalactan: Studies on Bioavailability and Pharmacokinetics.

Authors:  Mikhail V Khvostov; Sergey A Borisov; Tatjana G Tolstikova; Alexander V Dushkin; Biligma D Tsyrenova; Yulia S Chistyachenko; Nikolay E Polyakov; Galina G Dultseva; Andrey A Onischuk; Sergey V An'kov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

4.  Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.

Authors:  Marie-Laure Chaix; Didier Koumavi Ekouevi; Gilles Peytavin; François Rouet; Besigin Tonwe-Gold; Ida Viho; Laurence Bequet; Clarisse Amani-Bosse; Hervé Menan; Valériane Leroy; Christine Rouzioux; François Dabis
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

5.  Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma.

Authors:  R M van Praag; S Repping; J W de Vries; J M Lange; R M Hoetelmans; J M Prins
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

6.  A sensitive and specific liquid chromatography/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboons.

Authors:  Chen Ren; Patty Fan-Havard; Natalia Schlabritz-Loutsevitch; Yonghua Ling; Kenneth K Chan; Zhongfa Liu
Journal:  Biomed Chromatogr       Date:  2010-07       Impact factor: 1.902

7.  Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools.

Authors:  Sanjay U C Sankatsing; Patrick G Hoggard; Alwin D R Huitema; Rolf W Sparidans; Stephen Kewn; Kristel M L Crommentuyn; Joep M A Lange; Jos H Beijnen; David J Back; Jan M Prins
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Incidence and risk factors for nevirapine-associated rash.

Authors:  Monique M R de Maat; Rob ter Heine; Jan W Mulder; Pieter L Meenhorst; Albert T A Mairuhu; Eric C M van Gorp; Alwin D R Huitema; Jos H Beijnen
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

9.  Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals.

Authors:  Monique M R de Maat; Alwin D R Huitema; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Albert T A Mairuhu; Jos H Beijnen
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

10.  Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda.

Authors:  Laurence Ahoua; Gunar Guenther; Loretxu Pinoges; Paul Anguzu; Marie-Laure Chaix; Clotilde Le Tiec; Suna Balkan; David Olson; Charles Olaro; Mar Pujades-Rodríguez
Journal:  BMC Infect Dis       Date:  2009-06-03       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.